KARL SCHOENAFINGER,STEFANIE KEIL,MATTHIAS URMANN,HANS MATTER,MAIKE GLIEN,WOLFGANG WENDLER
申请号：
BRPI0821915
公开号：
BRPI0821915A2
申请日:
2008.12.12
申请国别(地区):
BR
年份:
2015
代理人:
摘要：
The invention relates to cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
